Express Mail No: EV 356815353 US

				ATTY. DOCKET NO.	APPLICATIO	N NO.			
		•		7969-100-999	To Be As	signed	1		
LIST OF	REFE	RENCES CITED BY A	PPLICANT	APPLICANT	<u> </u>				
((Jse se	veral sheets if necess	ary)	JACKSON et al.					
•				FILING DATE	GROUP				
				Concurrently herewith	To be ass	igned			
			U.S. P	PATENT DOCUMENTS					
PB/		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS		NG DATE PROPRIATE
	AA	5,071,962	12/10/91	Morrison et al.					
/PB/	AB	5,516,638	5/14/96	Umovitz et al.					
/PB/	AC	5,725,863	3/10/98	Daniels et al.					
/PB/	AD	5,965,141	10/12/99	Briles et al.					
/PB/	AE	5,976,544	11/2/99	Charles et al.					
	İ	00							
		VIII.	FOREIG	N PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRAN	SLATION
/PB/	AF	EP 0 818 681 A1	1/14/98	EP				YES	NO
/PB/	AG	WO 95/12411	5/11/95	PCT	11				
/PB/	AH	WO 96/31236	10/10/96	PCT					
/PB/	AI	WO 98/10789	3/19/98	PCT					
TEST.		OTHER REFERE	NCES (Inc	cluding Author, Title, Date, P	ertinent Pa	iges, E	tc.)		
/PB/	AJ	Birkelund et al. Infect Ir							-
/PB/	AK	Buendia et al. FEMS Mi	crobiol Lett.	150(1): 113-9 (1997).					
/PB/	AL	Caldwell et al., 1981, Inf	ect. and Immu	ın. <u>31</u> :1161-1176		<u> </u>			
/PB/	AM	Caldwell, et al., Infec. In	ımun., <u>31</u> (3):1	161-1176 (1981)					
/PB/	AN	Carlson et al., Infect Imn	nun. Vol. 65: 1	No. 6; p. 2080-2087 (1997)					
/PB/	AO	Cerrone et al., Infec. Imr	nun., <u>59</u> (1):79	-90 (1991)					
/PB/	AP	Chen et al., Molecular Microbiology 11(3):501-507 (1994)							
/PB/	AQ	Christiansen et al., Scand	J Infect Dis S	Suppl, 104:5-10 (1997)	· · · · · · ·				_
/PB/	AR	DeSa et al. Infect Immu	n. <u>63</u> (12): 491	2-6 (1995).			· · · · · · · · · · · · · · · · · · ·		
/PB/	AS	Deslauriers et al., Infect.	Immun. Vol.	64: No. 2; p. 434-440 (1996)		_			
/PB/	АТ	Herring et al., FEMS Mid	crobiol Letts.	65:153-158 (1989)			<u>. </u>		
/PB/	AU	Li et al. PNAS 77(6): 32	Li et al. PNAS 77(6): 3211-14 (1980)						
/PB/	AV	Murdin et al., Infec. Imm	Aurdin et al., Infec. Immun., <u>61(10):4406-4414 (1993)</u>						
/PB/	AW	Murdin et al., Infec. Imm	un., <u>63</u> (3):111	6-1121 (1995)					
/PB	AX	Pal et al., Infection & Im-	munity, 65: 33	361-3369, August (1997)					
/PB/	AY	Sandbulte et al., Veterina	ry Microbiolo	gy, 48:269-282 (1996)					

/PB/	AZ	Sexton et al. J. Immunol., 152(4):1861-	72 (1994)			
/PB/	BA	Stephens et al., J. Bacteriol 168:1277-8	Stephens et al., J. Bacteriol 168:1277-82 (1986)			
/PB/	ВВ	Su et al. PNAS 93: 11134-48 (1996)	_			
/PB/	BC	Swanson et al., Infec. Immun., 38(2):50	2-507 (1990)			
/PB/	BD	Tan et al., Infect Immun. 58(9) 3101-31	Tan et al., Infect Immun. 58(9) 3101-3108 (1990)			
/PB/	BE	Wagar et al., Infec. Immun., <u>56(7):1678-1684 (1988)</u>				
/PR/	BF	Zhang et al., Cell, <u>69</u> :861-869 (1992)				
/PB/	BG	Zhang et al., Nucleic Acids Res. 18(4):1	061 (1990)			
EXAMI	NER	/Padmavathi Baskar/	DATE CONSIDERED 07/18/2007			
*EXAMIN	ER: Init	tial if reference considered, whether or not considered. Include copy of this form	citation is in conformance with MPEP 609; Draw line through citation if not with next communication to applicant.			

Equivalent of Form PTO/SB/08A (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ostitute for form 1449A/PTO

NOV 1

FRAT & TRAS

Sheet

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

Complete if Known				
Application Number 10/766,711				
Filing Date	January 27, 2004			
First Named Inventor	W. James JACKSON			
Art Unit	1645			
Examiner Name	BASKAR, Padmavathi			
Attorney Docket Number	2479.0040003/ЕЈН/С-К			

			U.S. PATENT DO		
Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ^{2 (If Known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/PB/ /PB/	USI	4,427,782	01/24/1984	Caldwell et al.	or recevant rigares reppear
IPB/	US2	4,935,352	06/19/1990	Igarashi et al.	
	US3	5,565,352	10/15/1996	Hochstrasser et al.	;
/PB/	US4	5,871,977	02/16/1999	Kubota et al.	
/PB/	US5	6,642,023	11/04/2003	Jackson et al.	
	US6	6,887,843	05/03/2005	Jackson et al.	
1681	US7	5,849,306	12/15/1998	Sim et al.	
IPBI IPBI	US8	2004/0067524	11/04/2003	Jackson et al.	
1101	US9	2005/0048557 A1	03/03/2005	Jackson et al.	
			ļ		
			<u> </u>		
			 		
			ļ <u>.</u>		
		<u> </u>	<u> </u>		

		Fo	REIGN PATENT DO	DCUMENTS		_
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
/PB/		Country Code ³ Number ⁶ Kind Code ³ (if known)			Relevant Passages or Relevant Figures Appear	Te
	FP1	WO 94/01548	01/20/1994	Medical Research Council		
	ļ					

		1				\Box

602548_I

Examiner Signature	/Padmavathi Baskar/	Date Considered	07/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.

Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradernark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to re

Substitute for	substitute for form 1449B/PTO			Complete if Known		
FIRST S	IIDDI EN	#ENT	ΛI	Application Number	10/766,711	
				Filing Date	January 27, 2004	
INFORMATION DISCLOSURE				First Named Inventor	W. James JACKSON	
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1645			
		Examiner Name	BASKAR, Padmavathi			
Sheet	1	of	4	Attorney Docket Number	2479.0040003/ЕЛН/С-К	

	1 ~:	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/PB/	NPL1	AMERSDORFER, P., et al., "Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries," <i>Infect. Immun.</i> 65:3743-3752, American Society For Microbiology (September 1997)	
/PB/	NPL2	BARENKAMP, S.J., and ST. GEME III, J.W., "Identification of Surface-Exposed B-Cell Epitopes on High-Molecular-Weight Adhesion Proteins of Nontypeable <i>Haemophilus influenzae</i> ," <i>Infect. Immun.</i> 64:3032-3037, American Society For Microbiology (August 1996)	
/PB/	NPL3	BATTEIGER, B.E., et al., "Species-, Serogroup-, and Serovar-Specific Epitopes Are Juxtaposed in Variable Sequence Region 4 of the Major Outer Membrane Proteins of Some Chlamydia trachomatis Serovars," Infect. Immun. 64:2839-2841, American Society For Microbiology (July 1996)	
/PB/	NPL4	BAUGHN, R.E., et al., "Epitope Mapping of B-Cell Determinants on the 15-Kilodalton Lipoprotein of Treponema pallidum (Tpp15) with Synthetic Peptides," Infect. Immun. 64:2457-2466, American Society For Microbiology (July 1996)	
/PB/	NPL5	BROWN, D.R., et al., "Identification and Characterization of a Neutralizing Monoclonal Antibody Against Botulinum Neurotoxin, Serotype F, Following Vaccination With Active Toxin," Hybridoma 16:447-456, Mary Ann Leibert, Inc. (October 1997)	
/PB/	NPL6	BURNIE, J.P., et al., "Defining Antibody Targets in Streptococcus oralis Infection," Infect. Immun. 64:1600-1608, American Society For Microbiology (May 1996)	
/PB/	NPL7	CHOH, H.L., et al., "β-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities," <i>Proc. Natl. Acad. Sci. USA</i> 77:3211-3214, National Academy of Sciences (1980)	
/PB/	NPL8	CUNNINGHAM, M.W., et al., "Molecular Analysis of Human Cardiac Myosin-Cross-Reactive B- and T-Cell Epitopes of the Group A Streptococcal M5 Protein," Infect. Immun. 65:3913-3923, American Society For Microbiology (September 1997)	
/PB/	NPL9	DAVIES, D.R., and Cohen, G.H., "Interactions of protein antigens with antibodies," <i>Proc. Natl. Acad. Sci. USA 93</i> :7-12, National Academy of Sciences (January 1996)	
/PB/	NPL10	DE SA, C., "La protéine majeure de la membrane externe de <i>Chlamydia</i> : structure et fonctions," <i>Vet. Res. 27</i> :317-331, ZDP Sciences (February 1996)	

Examiner		Date	07/40/0007
	(Dadwayath) Dagland	Daic	07/18/2007
Signature	/Padmavathi Baskar/	Considered	01110/2001
		Communica	i

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE apond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to re-

Substitute for	Substitute for form 1449B/PTO			Complete if Known		
FIRST SUPPLEMENTAL				Application Number	10/766,711	
INFORMATION DISCLOSURE				Filing Date	January 27, 2004	
				First Named Inventor	W. James JACKSON	
	STATEMENT BY APPLICANT		Art Unit	1645		
(Use as many sheets as necessary)		Examiner Name	BASKAR, Padmavathi			
Sheet	2	of	4	Attorney Docket Number	2479.0040003/EJH/C-K	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/PB/	NPL11	DELVIG, A.A., et al., "Immune responses to linear epitopes on the PorB protein of Neisseria meningitidis in patients with systemic meningococcal disease," Microbiology 142:2491-2498, Society for General Microbiology (September 1996)	
/PB/	NPL12	DUIM, B., et al., "Fine Mapping of Outer Membrane Protein P2 Antigenic Sites Which Vary During Persistent Infection by Haemophilus influenzae," Infect. Immun. 64:4673-4679, American Society For Microbiology (November 1996)	
/PB/	NPL13	FAN, J., and Stephens, R.S., "Antigen Conformation Dependence of Chlamydia trachomatis Infectivity Neutralization," J. Infect. Dis. 176:713-721, University of Chicago Press (September 1997)	
/PB/	NPL14	GHADJARI, A., et al., "Epitope mapping Candida albicans proteinase (SAP 2)," FEMS Immunol. Med. Microbiol. 19:115-123, Elsevier Science (October 1997)	
/PB/	NPL15	GOODMAN, J.W., "Immunogenicity & Antigenicity," in Basic and Clinical Immunol., Stites, D.P., et al., eds., Appleton & Lange, Norwalk, CT, pp. 102-108 (1991)	
/PB/	NPL16	JANEWAY, C., et al., Immunogenicity,., John Wiley & Sons, Inc., New York, NY, pp. 65-71 (1989)	
/PB/	NPL17	LAINSON, F.A., et al., "Characterization of epitopes involved in the neutralization of Pasteurella haemolytica serotype A1 leukotoxin," Microbiology 142:2499-2507, Society for General Microbiology (September 1996)	
/PB/	NPL18	MÉCHIN, M., et al., "Identification of Surface-Exposed Linear B-Cell Epitopes of the Nonfimbrial Adhesin CS31A of Escherichia coli by Using Overlapping Peptides and Antipeptide Antibodies," Infect. Immun. 64:3555-3564, American Society for Microbiology (September 1996)	
/PB/	NPL19	MORRIS, G.E., Epitope Mapping Protocols, Morris, G.E., ed., Humana Press, Inc., Totowa, NJ, 5 pages (1996)	
/PB/	NPL20	OETTINGER, T., et al., "Characterization of the Delayed Type Hypersensitivity-Inducing Epitope of MPT64 from Mycobacterium tuberculosis," Scand. J. Immunol. 45:499-503, Blackwell Science, Ltd. (May 1997)	

Examiner Signature	/Padmavathi Baskar/	Date Considered	07/18/2007
-----------------------	---------------------	--------------------	------------

^{&#}x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)
Approved for use through 09/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB community. Under the Paperwork Reduction Act of 1995, no persons are required to re

Substitute for form 1449B/PTO				Complete if Known		
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			ΓΔΙ	Application Number	10/766,711	
				Filing Date	January 27, 2004	
				First Named Inventor	W. James JACKSON	
				Art Unit	1645	
(Use as many sheets as necessary)		Examiner Name	BASKAR, Padmavathi			
Sheet	3	of	4	Attorney Docket Number	2479.0040003/ЕЛН/С-К	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		
/PB/	NPL21	PAL, S., et al., "Monoclonal immunoglobulin A antibody to the major outer membrane protein of Chlamydia trachomatis mouse pneumonitis biovar protects mice against a genital chlamydial challenge," Vaccine 15:575-582, Elsevier Science (April 1997)		
/PB/	NPL22	READ, T.D., et al., "Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae," Nucleic Acids Res. 31:2134-2147, Oxford University Press (April 2003)		
/PB/	NPL23	ROITTE, I., et al., Immunology, Roitt, I., et al., eds., St. Louis, MO, CV. Mosby, pp. 7.1-7.10 (1989)		
/PB/	NPL24	SAINT-REMY, J.R., "Epitope mapping: a new method for biological evaluation and immunotoxicology," <i>Toxicology</i> 119:77-81, Elsevier Science (April 1997)		
/PB/	NPL25	TAKAHASHI, I., et al., "Epitope Maps of the Escherichia coli Heat-Labile Toxin B Subunit for Development of a Synthetic Oral Vaccine," Infect. Immun. 64:1290-1298, American Society for Microbiology (April 1996)		
/PB/	NPL26	WOOD, A.C., et al., "Identification of antigenic sites on staphylococcal enterotoxin B and toxoid," FEMS Immunol. Med. Microbiol. 17:1-10, Elsevier Science (January 1997)		
/PB/	NPL27	YANAGISAWA, S., et al., "Mapping of V _β 11 ⁺ helper T cell epitopes on mycobacterial antigen in mouse primed with Myobacterium tuberculosis," Int. Immunol. 9:227-237, Oxford University Press (February 1997)		
/PB/	NPL28	ZHAO, Q., et al., "Recall of Original Serologic Response after Challenge with Homologous and Heterologous Chlamydia trachomatis Serovars," J. Infect. Dis. 173:609- 618, The University of Chicago Press (March 1996)		
/PB/	NPL29	ZHONG, G., et al., "Antibody Recognition of a Neutralization Epitope on the Major Outer Membrane Protein of Chlamydia trachomatis," Infect. Immun. 62:1576-1583, American Society for Microbiology (May 1994)		
/PB/	NPL30	ZHU, Y., et al., "Identification of a Coccidioides immitis Antigen 2 Domain That Expresses B-Cell-Reactive Epitopes," Infect. Immun. 65:3376-3380, American Society for Microbiology (August 1997)		

Examiner	(Dardon and the Dardon)	Date					
Signature	/Padmavathi Baskar/		07/18/2007				
O.B. attace		Considered	*********				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)
Approved for use through 09/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE cond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to re

Substitute for form 1449B/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/766,711	
			Filing Date	January 27, 2004	
			First Named Inventor	W. James JACKSON	
			Art Unit	1645	
(Use as many sheets as necessary)		Examiner Name	BASKAR, Padmavathi		
Sheet	4	of 4	Attorney Docket Number	2479.0040003/ЕЈН/С-К	

NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume numbe publisher, city and/or country where published			f T²	
/PB/	NPL31	Copy of co-pending U.S. Application No. 08/942,596, inventors Jackson, W.J., et al., filed October 2, 1997 (NOT PUBLISHED)		
/PB/	NPL32	NCBI Entrez, GenBank Report, Accession No. R91549, Hillier, L., et al. (1995)		

603656_1

Examiner	(Dadmovathi Dagkar)	Date	
Signature	/Padmavathi Baskar/	Considered	07/18/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.